Procept BioRobotics completes enrollment in prostate cancer study

PROCEPT BioRobotics completed enrollment in its first WATER IV randomized study and received FDA IDE approval for a second randomized prostate cancer protocol, extending its Aquablation clinical program. The first study enrolled 280 patients versus radical prostatectomy, while the new trial will enroll up to 333 patients globally versus active surveillance over a 10-year follow-up. The backdrop is supportive: revenue grew 29% to $322 million over the last twelve months, and the company recently reported Q1 2026 EPS of $0.56 versus -$0.56 expected and revenue of $83.13 million versus $80.5 million consensus.

Analysis

The market is re-rating PRCT as a binary clinical/regulatory story with a long optionality tail, but the near-term equity move is being driven more by de-risking of the platform than by any immediate revenue inflection. Completion of enrollment removes one of the biggest overhangs for a small-cap medtech with a long-duration catalyst stack, and it likely compresses the discount rate investors have been applying to the prostate-cancer expansion thesis. The second protocol broadens the addressable opportunity, but it also increases execution complexity; the market is implicitly pricing a platform transition from BPH-only utility to a broader urology franchise.

The second-order winner is likely the installed base and salesforce efficiency: once clinicians are trained on Aquablation workflows for benign disease, conversion into adjacent indications can create a low-cost commercial upsell if the data support it. That said, this is not a clean “data readout” catalyst — it is a multi-year option on endpoints with meaningful clinical uncertainty, and the stock can mean-revert sharply if the next several quarters don’t show accelerating procedure adoption or if reimbursement commentary softens. Competitively, the biggest pressure is not another single device but the incumbent surgical standard’s response if physicians perceive the randomized evidence as credible; even modest practice-pattern shifts can matter because the category is procedure-volume driven.

The contrarian view is that the move may be ahead of the actual catalyst curve: the stock is now trading on a 2027 event while the company still needs to prove it can scale margins and convert clinical credibility into durable utilization growth. For a name with positive gross margin but negative earnings, any stumble in operating leverage, capital needs, or trial timelines can cut the multiple quickly. The setup is therefore attractive for event-driven traders, but less compelling for pure long-only holders unless they are underwriting a multi-year FDA-label and market-share expansion path.

Key Decisions for Investors

• Initiate a tactical long in PRCT only on pullbacks, targeting a 6-12 month horizon; use the current strength to wait for a better entry because the near-term upside is mostly multiple expansion, not fundamentals. Risk/reward is favorable only if you can tolerate a 15-20% drawdown on any trial or commercialization setback.
• Buy PRCT call spreads or risk-defined upside structures into the next 3-6 months rather than outright stock; this captures continued momentum while limiting exposure to a reversal if the market fades the newsflow.
• Pair trade: long PRCT / short a mature urology or surgical incumbent basket over the next 6-18 months. The thesis is that PRCT has a higher beta to clinical optionality, while incumbents face incremental share-risk if Aquablation data keep validating a quality-of-life advantage.
• If already long, trim into strength and hold a residual core position for the 2027 readout. The convexity is attractive, but the path is long and sentiment can mean-revert well before any definitive data.
• Set a downside risk trigger on any commentary suggesting slower procedure adoption or weaker reimbursement economics; that would invalidate the de-risking narrative faster than the trial schedule itself.